Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation
- PMID: 2666654
Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation
Abstract
To reassess predisposing factors in patients with systemic lupus erythematosus (SLE) who develop aseptic necrosis of bone, we studied 172 patients with SLE seen at our institution between 1975 and 1987 followed for longer than 1 year. Twenty-eight (16.3%) of these patients developed clinically apparent aseptic necrosis. In 12 of these 28 the continuous glucocorticosteroid dose was known. These 12 patients were compared to 15 controls with SLE followed for a minimum of 4.5 years for whom continuous glucocorticosteroid dosage was also known. We were unable to find any significant differences between patients with aseptic necrosis and controls in prevalence of specific lupus organ system involvement, Raynaud's phenomenon, or abnormal serological or hematological variables. Overall disease activity at the time of maximal glucocorticosteroid dosage did not differ significantly between the 2 groups but was slightly greater at the time SLE was diagnosed in the group with aseptic necrosis. Glucocorticosteroid intake during the first 1.5 years after diagnosis of SLE and during the third year after diagnosis was significantly greater for the patients with aseptic necrosis than for the control patients, as was glucocorticosteroid intake during the maximal 1, 3 and 6 months of therapy. We conclude that glucocorticosteroid intake is the major factor predisposing to aseptic necrosis in patients with SLE.
Similar articles
-
Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE.J Rheumatol. 1978 Summer;5(2):136-41. J Rheumatol. 1978. PMID: 671430
-
Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy.Arch Intern Med. 1978 May;138(5):750-4. Arch Intern Med. 1978. PMID: 646538
-
Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus.J Rheumatol. 2001 Apr;28(4):761-5. J Rheumatol. 2001. PMID: 11327247
-
Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review.Rheumatology (Oxford). 2007 Mar;46(3):539-44. doi: 10.1093/rheumatology/kel343. Epub 2006 Oct 13. Rheumatology (Oxford). 2007. PMID: 17043051 Review.
-
Aseptic bone necrosis in patients on glucocorticoid replacement therapy.Neth J Med. 1991 Oct;39(3-4):153-7. Neth J Med. 1991. PMID: 1791877 Review.
Cited by
-
Osteonecrosis in patients with SLE.Clin Rev Allergy Immunol. 2003 Aug;25(1):13-24. doi: 10.1385/CRIAI:25:1:13. Clin Rev Allergy Immunol. 2003. PMID: 12794257 Review.
-
Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication.Autoimmune Dis. 2012;2012:725249. doi: 10.1155/2012/725249. Epub 2012 Aug 5. Autoimmune Dis. 2012. PMID: 22919470 Free PMC article.
-
High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review.J Arthroplasty. 2015 Sep;30(9):1506-1512.e5. doi: 10.1016/j.arth.2015.03.036. Epub 2015 Apr 8. J Arthroplasty. 2015. PMID: 25900167 Free PMC article. Review.
-
Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis.Clin Rheumatol. 2018 Jan;37(1):5-11. doi: 10.1007/s10067-017-3820-5. Epub 2017 Sep 25. Clin Rheumatol. 2018. PMID: 28948379
-
Total hip arthroplasty for vascular necrosis of the femoral head in patients with systemic lupus erythematosus: a midterm follow-up study of 28 hips in 24 patients.Eur J Orthop Surg Traumatol. 2013 Jan;23(1):73-9. doi: 10.1007/s00590-012-0939-6. Epub 2012 Feb 5. Eur J Orthop Surg Traumatol. 2013. PMID: 23412411
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical